PAPA (Papa Medical) ROCE %: 76.70% (As of Mar. 2025)


What is Papa Medical ROCE %?

Papa Medical PAPA ROCE % is 76.70% as of Mar. 2025.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Papa Medical's annualized ROCE % for the quarter that ended in Mar. 2025 was 76.70%.

Papa Medical  (NAS:PAPA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Papa Medical ROCE % Related Terms

Papa Medical ROCE % Historical Data

* Premium members only.

The historical data trend for Papa Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Papa Medical ROCE % Chart

Papa Medical Annual Data
Trend Dec22 Dec23 Dec24
ROCE %
153.62 98.60 25.90

Papa Medical Quarterly Data
Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
ROCE % Get a 7-Day Free Trial Premium Member Only 56.43 30.62 38.48 -39.34 76.70

Papa Medical ROCE % Calculation

Papa Medical's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=1.035/( ( (11.515 - 8.127) + (19.416 - 14.813) )/ 2 )
=1.035/( (3.388+4.603)/ 2 )
=1.035/3.9955
=25.90 %

Papa Medical's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=3.724/( ( (19.416 - 14.813) + (19.672 - 14.564) )/ 2 )
=3.724/( ( 4.603 + 5.108 )/ 2 )
=3.724/4.8555
=76.70 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 76.70% mean?
Papa Medical (PAPA) has a ROCE % of 76.70% as of Mar. 2025.
Is Papa Medical's ROCE % too high?
Papa Medical's current ROCE % is 76.70%. The Tobacco Products industry median ROCE % is 17.46. Papa Medical's value of 76.70% is 339.3% above this industry median.
How does Papa Medical's ROCE % compare to ?
Papa Medical's ROCE % of 76.70% can be compared against companies in the Tobacco Products industry. The industry median ROCE % is 17.46. Papa Medical's value of 76.70% is 339.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Tobacco Products company?
The median ROCE % among Tobacco Products companies is 17.46, based on 46 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Papa Medical's current ROCE % of 76.70% is 339.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Tobacco Products industry, the median ROCE % is 17.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Papa Medical's current ROCE % is 76.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Papa Medical stock overvalued right now?
Papa Medical (PAPA) has a current ROCE % of 76.70%. The current ROCE % is 76.70% and 339.3% above the Tobacco Products industry median of 17.46. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Papa Medical (PAPA), the current ROCE % is 76.70% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Papa Medical Business Description

Comparable Companies
Address 202 North California Ave, City of Industry, CA, USA, 91744
Papa Medical Inc is the first end-to-end cannabis dosing solution provider in the U.S. that possesses the medical atomization or nebulizing background and sells nebulizers. The company deeply engages in key activities in the cannabis and consuming E-vapors industry, from research and development, formulation design, e-liquid production, and e-liquid filling to e-liquid co-packing services. It is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis E-vapors.